When was Crossbow founded?

Crossbow was founded in 2021 and raised its 1st funding round 2 years after it was founded.

Where is Crossbow located?

Crossbow is headquartered in Cambridge, United States.

How many employees does Crossbow have?

As of Mar 01, 2026, the latest employee count at Crossbow is 10 - 49.

Is Crossbow a funded company?

Crossbow is a funded company, having raised a total of $187M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jul 11, 2023.

How much is Crossbow worth?

The latest valuation of Crossbow is $***** as of Jul 11, 2023.

When was the latest funding round of Crossbow?

Crossbow's latest funding was a $***** Series B round on Mar 18, 2026, with participation from 10 investors. Its primary sector is Oncology. In United States, the Oncology sector has seen $6.54B in funding in 2026 to date.

Where does Crossbow rank among its competitors?

Crossbow ranks 349th amongst 3439 active competitors, of which 1134 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Crossbow?

Crossbow's top competitors include BeiGene, Jazz Pharmaceuticals and Kite Pharma. Among them, Immuneel secured the most recent funding round in June, 2026.

Crossbow - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of antibody therapies for cancer treatment. The company is advancing the development of novel therapies that potently target peptide-loaded major histocompatibility complexes (pMHCs) on cancer cells, using antibodies that mimic T-cell receptors (TCR-mimetics).

Website: www.crossbowtx.com/
Email ID: *****@crossbowtx.com
Part Of

Key Metrics

Founded Year

2021

Location

Cambridge, United States

Stage

Series B

Total Funding

$187M in 3 rounds

Latest Funding Round

Series B, Mar 18, 2026, $*****

Post Money Valuation

$***** as on Jul 11, 2023

Investors

Pfizer & 13 more

Ranked

349^th among 3439 active competitors

Employee Count

10 - 49 as on Mar 01, 2026

Similar Companies

BeiGene & 671 more

View Crossbow's full profile

Crossbow has raised a total funding of $187M over 3 rounds. Its first funding round was on Jul 11, 2023. Its latest funding round was a Series B round on Mar 18, 2026 for $*****. 10 investors participated in its latest round. Crossbow has 14 institutional investors.

Here is the list of recent funding rounds of Crossbow:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 18, 2026	8620878	Series B	1486140	3833442	4892971	1987699
Sep 17, 2025	7913752	Series A	8643410	3779529	1490146	1253368
Jul 11, 2023	5104494	Series A	8265212	9647244	Pfizer	Polaris Partners & 4 more

Access funding benchmarks and valuations. Sign up today!

View details of Crossbow's funding rounds and investors

Crossbow's employee count trend

Crossbow has 10 - 49 employees as of Mar 26. Here is Crossbow's employee count trend over the years:

Uncover Crossbow's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Crossbow include BeiGene, Jazz Pharmaceuticals and Kite Pharma. Here is the list of Top 10 competitors of Crossbow, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
2nd	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
3rd	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Amgen Business Development ... & 10 others	76/100
4th	Attovia 2023, Fremont (United States), Public	Developer of antibody-based therapeutics for immune-mediated diseases and oncology	$255M	Deep Track Capital, Goldman Sachs Asset Management ... & 13 others	72/100
5th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
10th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
349th	Crossbow 2021, Cambridge (United States), Series B	Developer of antibody therapies for cancer treatment	$187M	BVF Partners, Lilly & 12 others	56/100